A detailed history of Virtus ETF Advisers LLC transactions in Merus N.V. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 1,595 shares of MRUS stock, worth $66,750. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,595
Previous 1,570 1.59%
Holding current value
$66,750
Previous $92,000 14.13%
% of portfolio
0.04%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$47.19 - $58.84 $1,179 - $1,471
25 Added 1.59%
1,595 $79,000
Q2 2024

Aug 14, 2024

SELL
$39.81 - $60.2 $74,086 - $112,032
-1,861 Reduced 54.24%
1,570 $92,000
Q1 2024

May 15, 2024

SELL
$28.03 - $51.82 $6,474 - $11,970
-231 Reduced 6.31%
3,431 $154,000
Q4 2023

Feb 15, 2024

SELL
$20.06 - $28.66 $1,384 - $1,977
-69 Reduced 1.85%
3,662 $100,000
Q3 2023

Nov 07, 2023

SELL
$20.13 - $27.29 $7,488 - $10,151
-372 Reduced 9.07%
3,731 $87,000
Q2 2023

Aug 14, 2023

SELL
$18.33 - $27.18 $58,692 - $87,030
-3,202 Reduced 43.83%
4,103 $108,000
Q1 2023

May 15, 2023

SELL
$14.25 - $20.5 $39,914 - $57,420
-2,801 Reduced 27.72%
7,305 $134,000
Q4 2022

Feb 14, 2023

BUY
$12.8 - $23.66 $62,540 - $115,602
4,886 Added 93.6%
10,106 $156,000
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $689 - $1,070
37 Added 0.71%
5,220 $105,000
Q2 2022

Aug 12, 2022

SELL
$13.98 - $29.25 $4,613 - $9,652
-330 Reduced 5.99%
5,183 $117,000
Q1 2022

May 16, 2022

SELL
$23.58 - $30.91 $7,781 - $10,200
-330 Reduced 5.65%
5,513 $146,000
Q4 2021

Feb 14, 2022

SELL
$20.0 - $32.29 $70,960 - $114,564
-3,548 Reduced 37.78%
5,843 $186,000
Q3 2021

Nov 15, 2021

SELL
$16.48 - $27.23 $7,992 - $13,206
-485 Reduced 4.91%
9,391 $207,000
Q2 2021

Aug 10, 2021

BUY
$20.0 - $25.48 $197,520 - $251,640
9,876 New
9,876 $208,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $1.92B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.